Last updated: 23 January 2023 at 9:04pm EST

Dr. Roni Mamluk Ph.D. Net Worth




The estimated Net Worth of Roni Mamluk is at least $1.64 Million dollars as of 22 February 2021. Dr Mamluk owns over 33,126 units of Ayala Pharmaceuticals stock worth over $72,673 and over the last 9 years he sold AYLA stock worth over $930,844. In addition, he makes $635,601 as Pres and CEO & Director at Ayala Pharmaceuticals.

Dr D AYLA stock SEC Form 4 insiders trading

Dr has made over 15 trades of the Ayala Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 33,126 units of AYLA stock worth $617,137 on 22 February 2021.

The largest trade he's ever made was exercising 82,186 units of Ayala Pharmaceuticals stock on 20 February 2020 worth over $7,397. On average, Dr trades about 12,032 units every 45 days since 2016. As of 22 February 2021 he still owns at least 145,345 units of Ayala Pharmaceuticals stock.

You can see the complete history of Dr Mamluk stock trades at the bottom of the page.





Dr. Roni Mamluk Ph.D. biography

Dr. Roni Mamluk Ph.D. is the Pres, CEO & Director at Ayala Pharmaceuticals.

What is the salary of Dr D?

As the Pres and CEO & Director of Ayala Pharmaceuticals, the total compensation of Dr D at Ayala Pharmaceuticals is $635,601. There are 1 executives at Ayala Pharmaceuticals getting paid more, with Yossi Maimon CPA, M.B.A., CPA, MBA having the highest compensation of $692,182.



How old is Dr D?

Dr D is 54, he's been the Pres and CEO & Director of Ayala Pharmaceuticals since . There are 1 older and 3 younger executives at Ayala Pharmaceuticals. The oldest executive at Ayala Pharmaceuticals, Inc. is Dr. Gary B. Gordon M.D., Ph.D., 68, who is the Chief Medical Officer.

Insiders trading at Ayala Pharmaceuticals

Over the last 5 years, insiders at Ayala Pharmaceuticals have traded over $930,844 worth of Ayala Pharmaceuticals stock and bought 1,575,250 units worth $23,628,700 . The most active insiders traders include Growth Fund Limited Partner..., Murray A Goldberg, and Growth Fund Limited Partner.... On average, Ayala Pharmaceuticals executives and independent directors trade stock every 37 days with the average trade being worth of $102,203. The most recent stock trade was executed by Gary B. Gordon on 24 February 2021, trading 3,000 units of AYLA stock currently worth $15,480.



What does Ayala Pharmaceuticals do?

Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.



What does Ayala Pharmaceuticals's logo look like?

Ayala Pharmaceuticals, Inc. logo

Complete history of Dr Mamluk stock trades at Chiasma Inc and Ayala Pharmaceuticals

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
22 Feb 2021 Roni Mamluk
President and CEO
Sale 33,126 $18.63 $617,137
22 Feb 2021
145,345
20 Jan 2021 Roni Mamluk
President and CEO
Sale 20,872 $15.03 $313,706
20 Jan 2021
178,471
9 Feb 2021 Roni Mamluk
Director
Option 27,981 $1.85 $51,765
9 Feb 2021
27,981
20 Feb 2020 Roni Mamluk
Director
Option 82,186 $0.09 $7,397
20 Feb 2020
82,186
20 Dec 2019 Roni Mamluk
Director
Option 61,139 $0.09 $5,503
20 Dec 2019
61,139
16 Oct 2019 Roni Mamluk
Director
Option 10,000 $0.09 $900
16 Oct 2019
10,000
20 Sep 2019 Roni Mamluk
Director
Option 50,000 $0.09 $4,500
20 Sep 2019
50,000
16 Jul 2019 Roni Mamluk
Director
Option 10,000 $0.09 $900
16 Jul 2019
10,000
16 Apr 2019 Roni Mamluk
Director
Option 10,000 $0.09 $900
16 Apr 2019
10,000
5 Mar 2019 Roni Mamluk
Director
Option 5,000 $0.09 $450
5 Mar 2019
5,000
22 Jan 2019 Roni Mamluk
Director
Option 5,000 $0.09 $450
22 Jan 2019
5,000
18 Jun 2018 Roni Mamluk
Director
Option 2,389 $0.09 $215
18 Jun 2018
2,389
19 Mar 2018 Roni Mamluk
Director
Option 2,389 $0.09 $215
19 Mar 2018
2,389
18 Dec 2017 Roni Mamluk
Director
Option 2,389 $0.09 $215
18 Dec 2017
2,389
24 Oct 2017 Roni Mamluk
Director
Option 2,389 $0.09 $215
24 Oct 2017
2,389


Ayala Pharmaceuticals executives and stock owners

Ayala Pharmaceuticals executives and other stock owners filed with the SEC include: